Hantaan virus vaccine - GreenCross Vaccine

Drug Profile

Hantaan virus vaccine - GreenCross Vaccine

Alternative Names: Hantaan virus vaccine; Hantavax; ROK 84-105

Latest Information Update: 23 Sep 2015

Price : $50

At a glance

  • Originator GreenCross Vaccine
  • Developer Berna Biotech Korea Corp
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hantaan virus infections

Most Recent Events

  • 23 Sep 2015 Green Cross plans a phase III trial in Hantaan virus infections (Prevention) in South Korea (IM or SC) (NCT02553837)
  • 31 Oct 2002 Rhein Biotech has been acquired by Berna Biotech
  • 23 Sep 1999 Investigation in Hantaan virus infections in Yugoslavia (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top